Congestive Heart Failure, Diastole
Conditions
Keywords
controlled clinical trial, Diastole, Echocardiography, exercise tolerance, Heart Failure, Congestive, Receptors, Aldosterone
Brief summary
The primary purpose of this study is to determine whether eplerenone has a beneficial effect on improving exercise ability in patients with diastolic heart failure.
Detailed description
The objectives of this study are: 1) To evaluate the effect of eplerenone, an aldosterone antagonist, on intermediate functional outcomes in patients with DHF (diastolic heart failure); 2) To evaluate the effect of eplerenone, an aldosterone antagonist, on echocardiographic measures of diastolic dysfunction in patients with DHF. The study is an double-blind, placebo-controlled study evaluating the effects of eplerenone compared to placebo in patients with DHF. A total of 48 patients with DHF will be randomized in a 1:1 ratio to 1) Placebo (n=24) or to 2) Eplerenone (n=24) in a dose of 25 mg a day for the first 2 weeks followed by uptitration to 50 mg a day for 22 weeks. The primary outcome is an improvement in functional capacity, measured by the distance covered in a 6-minute walk test. Secondary Outcomes include : Change echocardiographic measures of diastolic dysfunction, change in levels of B-type natriuretic peptide (BNP)and change in quality of life.
Interventions
DRUGEplerenone
aldosterone receptor blocker
DRUGPlacebo
matching placebo
Sponsors
US Department of Veterans Affairs
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. All patients must have DHF as defined by all 3 of the following criteria: i)Presence of clinical heart failure for greater than or equal to 2 months before the screening visit. At the time of enrollment they should have NYHA functional class II or III heart failure symptoms such as dyspnea, fatigue on exertion, paroxysmal nocturnal dyspnea, and orthopnea. ii)Left ventricular ejection fraction greater than or equal to 50% (by echo, radionuclide angiography or contrast angiography) within 2 months of screening iii) BNP (brain natriuretic peptide) greater than or equal to 62 pg/ml within 2 months of screening 2. Patients euvolemic on clinical examination. If patients are not euvolemic, all attempts will be made to achieve a euvolemic state with change in diuretic doses prior to enrollment into the study 3. Systolic blood pressure less than or equal to 150 mmHg and diastolic blood pressure less than or equal to 95 mmHg for 4 weeks prior to and at the time of enrollment 4. Able to walk at least 50 m at the time of enrollment 5. All patients will be required to be on ACE inhibitors or angiotensin receptor blockers for at least 4 weeks prior to enrollment
Exclusion criteria
1. Patients requiring eplerenone or spironolactone for treatment of other comorbid illnesses, e.g. ascites due to cirrhosis. Also, patients with severe hepatic impairment will not be included. 2. Contraindication to eplerenone therapy with creatinine \> 2.5 mg/dl or serum potassium \> 5.0 mEq/L or creatinine clearance \< 30 ml/min/1.73 m2 or intolerance to eplerenone or spironolactone in the past 3. Significant valvular heart disease, pericardial disease or severe chronic lung disease with cor pulmonale, as the cause of symptoms and signs of CHF 4. Patients with technically inadequate echocardiographic windows or patients with severe mitral annular calcification 5. Unstable angina or MI within 4 weeks prior to enrollment 6. Patient with severe peripheral vascular disease and claudication or other physical conditions that will limit the distance walked by them 7. Pregnant or lactating females 8. History of alcohol or substance abuse or history of repeated non-compliance with medications 9. History of cancer within 3 years (other than resected cutaneous basal or squamous cell carcinoma) 10. Participation in any other drug trial within 30 days prior to enrollment 11. Inability to provide informed consent 12. On drugs that are strong inhibitors of CYP3A4 such as ketoconazole, itraconazole, nefazodone, trolandeomycin, clarithromycin, ritonavir, nelfinavir etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Six Minute Walk Distance from baseline to 24 weeks after randomization | 24 weeks | change in six minute walk distance between the placebo and spironolactone group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in left ventricular stiffness at 24 weeks, Change in other echocardiographic measures of diastolic dysfunction at 24 weeks, Change in levels of B-type natriuretic peptide (BNP) at 24 weeks; Change in quality of life at 24 weeks | 24 weeks | change in above echocardiogtraphic measures between placebo and spironolactone group |
Countries
United States
Outcome results
None listed